High EIF4A3 expression was associated with poor outcomes of anti-PD-1 treatment in melanoma and glioblastoma, but showed positive outcomes of adoptive T cell therapy and anti-PD-1 treatment in melanoma. This evidence concerns the gene EIF4A3 and glioblastoma.